Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
The Australian Government has published the Final Progress Report for Australia’s First National Antimicrobial Resistance Strategy 2015–2019 detailing its efforts to limit the incidence of antimicrobial resistance (AMR) in Australia.
The report highlights activities implemented between 2017 and 2019 in the human and animal health, food production and the environment.
Looking ahead, the Australian Government last year announced more than $22.5 million over four years in the 2020–21 Budget to implement an effective strategic framework for addressing AMR.
Botanix supports all efforts by the government and industry to address this pressing global health emergency. We are proud to be doing our part in the development of our BTX 1801 antimicrobial platform program too – most recently, we published world-first human data showing that our synthetic CBD-based ointment/gel formula can effectively eradicate Staphylococcus Aureus.
https://botanixpharma.com/wp-content/uploads/BOT_Progress-Report_FB.png788940Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-03-25 00:38:102023-03-13 21:16:44Progress Report for Australia’s First National AMR Strategy
Botanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, presented at the ASX Small and Mid-Cap Conference today.
View the presentation here:
https://botanixpharma.com/wp-content/uploads/FB_BOT_NEW.png788940Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-03-16 00:00:512023-03-13 21:16:44Presentation: ASX Small and Mid-Cap Conference
Article extract | “Novartis’ acquisition represents a double-down on an antibiotics field facing an existential crisis from resistant “super bugs” that have sent most major drugmakers running for the hills — including Novartis, which dumped its antibiotic R&D program in 2018. But adding ever-greater volume to their generic antibiotics portfolio could offer Novartis some bottom-line value in the dwindling space.”
Click through to read the full article on Endpoints News.
https://botanixpharma.com/wp-content/uploads/AdobeStock_226352071-scaled.jpeg17072560Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-02-12 21:24:042023-03-13 21:16:44Novartis’ Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes
Click through to read the full article on Stockhead.
https://botanixpharma.com/wp-content/uploads/Screen-Shot-2021-02-23-at-11.49.33-am.png11641518Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-02-05 12:49:172023-03-13 21:16:44ScoPo’s powerplays: Jazz Pharma’s $9.4b deal highlights pot plays
GW Pharma $GWPH, the UK biotech that caused a sensation of sorts with the approval of the world’s first cannabinoid med, is being bought out.
Jazz Pharmaceuticals came up with the winning number, agreeing to acquire GW for a total of $7.2 billion — $6.7 billion net of cash. GW agreed to a price of $200 cash and $20 in stock for the acquisition. This is the second biotech M&A deal of the week, which will likely portend more such deals to come.’
Click through to read the full article on Endpoints News here.
https://botanixpharma.com/wp-content/uploads/AdobeStock_300051426-1-scaled.jpeg12802560Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2021-02-03 20:54:502023-03-13 21:16:44Endpoints News | Jazz vaults into the cannabinoid field with $7.2B GW Pharma buyout
Progress Report for Australia’s First National AMR Strategy
/in ASX Releases, Featured, Latest News /by Haley ChartresThe Australian Government has published the Final Progress Report for Australia’s First National Antimicrobial Resistance Strategy 2015–2019 detailing its efforts to limit the incidence of antimicrobial resistance (AMR) in Australia.
The report highlights activities implemented between 2017 and 2019 in the human and animal health, food production and the environment.
Looking ahead, the Australian Government last year announced more than $22.5 million over four years in the 2020–21 Budget to implement an effective strategic framework for addressing AMR.
Botanix supports all efforts by the government and industry to address this pressing global health emergency. We are proud to be doing our part in the development of our BTX 1801 antimicrobial platform program too – most recently, we published world-first human data showing that our synthetic CBD-based ointment/gel formula can effectively eradicate Staphylococcus Aureus.
Download Australian Government’s Progress Report here.
Presentation: ASX Small and Mid-Cap Conference
/in Featured, Latest News, News /by Haley ChartresBotanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, presented at the ASX Small and Mid-Cap Conference today.
View the presentation here:
Novartis’ Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes
/in Featured, Latest News, News /by Haley ChartresArticle extract | “Novartis’ acquisition represents a double-down on an antibiotics field facing an existential crisis from resistant “super bugs” that have sent most major drugmakers running for the hills — including Novartis, which dumped its antibiotic R&D program in 2018. But adding ever-greater volume to their generic antibiotics portfolio could offer Novartis some bottom-line value in the dwindling space.”
Click through to read the full article on Endpoints News.
ScoPo’s powerplays: Jazz Pharma’s $9.4b deal highlights pot plays
/in Featured, Latest News, News /by Haley Chartres‘A huge acquisition in the international medical cannabis sector is set to give tailwinds to several ASX-listed marijuana companies, Scott Power says.
Ireland-based Jazz Pharmaceuticals (NASDAQ:JAZZ) this week agreed to buy cannabinoid drugmaker GW Pharmaceuticals (NASDAQ:GWPH) for $US7.2 billion ($9.4 billion) – a 50 per cent premium to GW’s closing price on Tuesday.’
Click through to read the full article on Stockhead.
Endpoints News | Jazz vaults into the cannabinoid field with $7.2B GW Pharma buyout
/in Featured, Latest News, News /by Haley ChartresGW Pharma $GWPH, the UK biotech that caused a sensation of sorts with the approval of the world’s first cannabinoid med, is being bought out.
Jazz Pharmaceuticals came up with the winning number, agreeing to acquire GW for a total of $7.2 billion — $6.7 billion net of cash. GW agreed to a price of $200 cash and $20 in stock for the acquisition. This is the second biotech M&A deal of the week, which will likely portend more such deals to come.’
Click through to read the full article on Endpoints News here.
Why the Botanix (ASX:BOT) share price is rocketing 31%was higher today
/in Featured, Latest News, News /by Haley Chartres‘The Botanix Pharmaceuticals (ASX:BOT) share price has returned from its trading halt with a bang on Wednesday.
In morning trade, the clinical stage synthetic cannabinoid company’s shares are up 31% to a record high of 19 cents.’
Click through to read the full article on The Motley Fool.